DRG Is Launching Innovative Traumatic Brain Injury (TBI) Test Panel at MEDLAB in Dubai

January 31, 2025 01:00 PM GMT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 DRG Is Launching Innovative Traumatic Brain Injury (TBI) Test Panel at MEDLAB in Dubai
Image source: Kalkine Media

MARBURG, Germany, Jan. 31, 2025 /PRNewswire/ -- DRG Instruments GmbH ("DRG") has been a top developer and manufacturer of immunoassays for over 50 years. The company is creating a new division, DRG Neuroscience, and the new division is presenting on the market its fully automated CLIA tests for evaluating suspected Traumatic Brain Injury (TBI) - the GFAP and UCH-L1 combo Tests. These tests are designed for use on DRG's automated CLIA platform, DxDATA™, enabling the measurement of GFAP and UCH-L1 blood levels within 30 minutes when patients' serum samples are collected within 12 hours of suspected traumatic brain injury. By providing fast and accurate TBI assessments, these tests increase the likelihood of immediate and effective treatment while reducing the need for radiation-based diagnostic imaging for suspected TBI.

"We are excited to bring these innovative TBI solutions to the global market," said Joerg Schloesser, Managing Director and VP of Commercial. "By leveraging automated testing and rapid turnaround times, we can help healthcare professionals make quicker, more informed decisions. Our mission is to advance patient care for those affected by traumatic brain injuries worldwide."

DRG's TBI Tests are CE-marked and have been verified to meet CLSI (Clinical and Laboratory Standards Institute) requirements. They are intended for use in a clinical laboratory setting and are indicated for patients aged 18 years or older.

To learn more about the test availability in your region or for more information about DRG's TBI Tests, please contact our Sales Representative or email [email protected].

DRG will also showcase the TBI tests at the upcoming MEDLAB Middle East, which will take place at the Dubai World Trade Centre from February 3 - 6 (Hall 1, Booth G50). The Product Development Team will be on hand to answer any questions about the TBI tests.

About DRG Instruments GmbH 

DRG Instruments GmbH, was established in 1973 and is based in Marburg. Since 1990, DRG Instruments has developed and manufactured innovative immunoassays, both for routine and research applications, with distribution partners in over 120 countries. DRG is also the manufacturer of the DRG:HYBRiD-XL®, a fully automated analyzer for immunoassays and clinical chemistry. DRG is an ISO 13485-certified company and operates in accordance with the FDA 21 CFR 820 Quality System Regulation. To learn more, visit https://www.drg-diagnostics.de/,  or follow us on LinkedIn,


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Recent Articles

Investing Tips

Previous Next